Update on the Progress of Musashi-2 in Malignant Tumors
Since the discovery of the Musashi (MSI) protein, its ability to affect the mitosis of Drosophila progenitor cells has garnered significant interest among scientists. In the following 20 years, it has lived up to expectations. A substantial body of evidence has demonstrated that it is closely relate...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-01-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/30/1/10.31083/FBL24928 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586506406985728 |
|---|---|
| author | Yiting Niu Tao Zhou Yanjun Li |
| author_facet | Yiting Niu Tao Zhou Yanjun Li |
| author_sort | Yiting Niu |
| collection | DOAJ |
| description | Since the discovery of the Musashi (MSI) protein, its ability to affect the mitosis of Drosophila progenitor cells has garnered significant interest among scientists. In the following 20 years, it has lived up to expectations. A substantial body of evidence has demonstrated that it is closely related to the development, metastasis, migration, and drug resistance of malignant tumors. In recent years, research on the MSI protein has advanced, and many novel viewpoints and drug resistance attempts have been derived; for example, tumor protein p53 mutations and MSI-binding proteins lead to resistance to protein arginine N-methyltransferase 5-targeted therapy in lymphoma patients. Moreover, the high expression of MSI2 in pancreatic cancer might suppress its development and progression. As a significant member of the MSI family, MSI2 is closely associated with multiple malignant tumors, including hematological disorders, common abdominal tumors, and other tumor types (e.g., glioblastoma, breast cancer). MSI2 is highly expressed in the majority of tumors and is related to a poor disease prognosis. However, its specific expression levels and regulatory mechanisms may differ based on the tumor type. This review summarizes the research progress related to MSI2 in recent years, including its occurrence, migration mechanism, and drug resistance, as well as the prospect of developing tumor immunosuppressants and biomarkers. |
| format | Article |
| id | doaj-art-52e52b431fc0446bb2948f4eda82cc77 |
| institution | Kabale University |
| issn | 2768-6701 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj-art-52e52b431fc0446bb2948f4eda82cc772025-01-25T08:55:52ZengIMR PressFrontiers in Bioscience-Landmark2768-67012025-01-013012492810.31083/FBL24928S2768-6701(24)01442-4Update on the Progress of Musashi-2 in Malignant TumorsYiting Niu0Tao Zhou1Yanjun Li2Department of Hepatobiliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032 Taiyuan, Shanxi, ChinaDepartment of Hepatobiliary Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032 Taiyuan, Shanxi, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032 Taiyuan, Shanxi, ChinaSince the discovery of the Musashi (MSI) protein, its ability to affect the mitosis of Drosophila progenitor cells has garnered significant interest among scientists. In the following 20 years, it has lived up to expectations. A substantial body of evidence has demonstrated that it is closely related to the development, metastasis, migration, and drug resistance of malignant tumors. In recent years, research on the MSI protein has advanced, and many novel viewpoints and drug resistance attempts have been derived; for example, tumor protein p53 mutations and MSI-binding proteins lead to resistance to protein arginine N-methyltransferase 5-targeted therapy in lymphoma patients. Moreover, the high expression of MSI2 in pancreatic cancer might suppress its development and progression. As a significant member of the MSI family, MSI2 is closely associated with multiple malignant tumors, including hematological disorders, common abdominal tumors, and other tumor types (e.g., glioblastoma, breast cancer). MSI2 is highly expressed in the majority of tumors and is related to a poor disease prognosis. However, its specific expression levels and regulatory mechanisms may differ based on the tumor type. This review summarizes the research progress related to MSI2 in recent years, including its occurrence, migration mechanism, and drug resistance, as well as the prospect of developing tumor immunosuppressants and biomarkers.https://www.imrpress.com/journal/FBL/30/1/10.31083/FBL24928musashi-2hepatocellular carcinomacancerepithelial–mesenchymal transition |
| spellingShingle | Yiting Niu Tao Zhou Yanjun Li Update on the Progress of Musashi-2 in Malignant Tumors Frontiers in Bioscience-Landmark musashi-2 hepatocellular carcinoma cancer epithelial–mesenchymal transition |
| title | Update on the Progress of Musashi-2 in Malignant Tumors |
| title_full | Update on the Progress of Musashi-2 in Malignant Tumors |
| title_fullStr | Update on the Progress of Musashi-2 in Malignant Tumors |
| title_full_unstemmed | Update on the Progress of Musashi-2 in Malignant Tumors |
| title_short | Update on the Progress of Musashi-2 in Malignant Tumors |
| title_sort | update on the progress of musashi 2 in malignant tumors |
| topic | musashi-2 hepatocellular carcinoma cancer epithelial–mesenchymal transition |
| url | https://www.imrpress.com/journal/FBL/30/1/10.31083/FBL24928 |
| work_keys_str_mv | AT yitingniu updateontheprogressofmusashi2inmalignanttumors AT taozhou updateontheprogressofmusashi2inmalignanttumors AT yanjunli updateontheprogressofmusashi2inmalignanttumors |